Skip to content
Biodatica
Start free

Daiichi Sankyo

San Francisco, California

OncologyPhase IIIListed · DSNKY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

5w agoTrial registeredJun 12, 2026Source filing (opens the source filing in a new tab)

Momentum

67no change

Momentum 67 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Mar 4, 2022

    Metastatic Non Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

    ClinicalTrials.gov · NCT05215340 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Feb 10, 2020

    Breast Cancer, Non-small Cell Lung Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT04042701 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources